Publications
- PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated? Czech atherosclerosis society statement2016 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Extracorporeal LDL-cholesterol elimination (25 years of experience in CZ)2009 | First Faculty of Medicine
- Therapeutic plasmapheresis and more specific methods of extracorporeal LDL-cholesterol elimination2009 | First Faculty of Medicine
- Hypolipidemic drugs and diabetes mellitus2009 | First Faculty of Medicine
- Reological efect of extracorporeal elimination of LDL cholesterol in patient with peripheral arterial occlusive disease (PAOD) and diabetes mellitus (DM)2008 | First Faculty of Medicine
- Changes of metabolism and hemostasis in familial hypercholetsrolemia treated with LDL-apheresis2007 | First Faculty of Medicine
- LDL apheresis - evaluation of the results from 1000 performed procedures +12005 | First Faculty of Medicine
- The Impact of Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia2024 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance2023 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Second Faculty of Medicine
- Statement CSAT on Consensus statement of the European Atherosclerosis Society: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis2023 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University
Loading network view...